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Reproductive function is regulated by the activity of the
hypothalamic–pituitary–gonadal axis. Gonadotrophin-releasing
hormone (GnRH) is secreted by GnRH neurone axon terminals at
the median eminence and regulates pituitary gonadotrophin syn-
thesis and secretion. GnRH neurone cell bodies are primarily located
in the basal forebrain with particular densities of neurones located
in the diagonal band of Broca (DBB), the medial septal nuclei and
the medial preoptic area (1–3).
Expression of the GnRH gene is anatomically very limited within
the central nervous system. It is estimated that as few as 800
neurones express the gene in the mouse brain (4). Transgenic
animal studies using various reporter genes have demonstrated that
cell-speciﬁc expression of the mouse GnRH gene in the adult
hypothalamus is regulated by the proximal 3446 base pairs of the
mouse promoter (5–8).
Targeted gene disruption has been an important tool in elucidat-
ing the physiological role for a number of genes. However, this
process produces animals in which all of the tissues and cells
of the body possess the deleted gene. A number of investigators
have deleted genes in speciﬁc tissue and cell types using the the
Cre⁄loxP system. This system uses the targeted expression of the
CRE bacteriophage recombinase to recognise consensus loxP target
sequences that have been inserted into the gene of interest (9, 10).
By crossing a mouse containing a transgene expressing CRE under
the control of a cell-speciﬁc promoter with a mouse containing a
gene ﬂanked by loxP elements, an animal in which the desired gene
is deleted only in the tissue of interest can be obtained. Site spe-
ciﬁc recombination using the Cre⁄LoxP system (11, 12) has been
performed by a number of investigators to produce neurone (13),
muscle (14), pancreatic b-cell (15, 16), kidney (17) and liver
(16)-speciﬁc gene deletions in mice.
In the present study, we report the development of a trans-
genic mouse line that expresses the CRE bacterial recombinase in
a GnRH neurone-speciﬁc manner. Using the 3446 bp mouse GnRH
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Gonadotrophin-releasing hormone (GnRH) neurones located within the brain are the ﬁnal neu-
roendocrine output regulating the reproductive hormone axis. Their small number and scattered
distribution in the hypothalamus make them particularly difﬁcult to study in vivo. The Cre⁄loxP
system is a valuable tool to delete genes in speciﬁc cells and tissues. We report the production
of two mouse lines that express the CRE bacteriophage recombinase in a GnRH-speciﬁc manner.
The ﬁrst line, the GnRH-CRE mouse, contains a transgene in which CRE is under the control of
the murine GnRH promoter and targets CRE expression speciﬁcally to GnRH neurones in the
hypothalamus. The second line, the GnRH-CRETeR mouse, uses the same murine GnRH promoter
to target CRE expression to GnRH neurones, but is modiﬁed to be constitutively repressed by a
tetracycline repressor (TetR) expressed from a downstream tetracycline repressor gene engi-
neered within the transgene. GnRH neurone-speciﬁc CRE expression can therefore be induced
by treatment with doxycycline which relieves repression by TetR. These GnRH-CRE and GnRH-
CRETeR mice can be used to study the function of genes expressed speciﬁcally in GnRH
neurones. The GnRH-CRETeR mouse can be used to study genes that may have distinct roles in
reproductive physiology during the various developmental stages.
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expressed in GnRH neurones (GnRH-Cre) were produced. These
mice are similar to mice produced in other studies (18–21).
A transgenic mouse in which the transgene is engineered to be
inducible by treatment with doxycycline allowing for temporal
regulation of GnRH neurone speciﬁc Cre-mediated, conditional
gene excision in mice (GnRH-CRETeR) was also developed. This
allows for the gene recombination to occur at the desired time
during the development of the mouse (22).
The production of mice containing GnRH neurone speciﬁc dele-
tions of genes could prove valuable to our understanding of molec-
ular and cellular elements that regulate GnRH neuronal
development and function. The present study provides the initial
characterisation of the two mouse lines.
Materials and methods
Transgene production
The GnRH-CRE transgene was produced by using the )3446⁄+28mGnRH
promoter fragment (generous gift from Dr Donald DeFranco) cloned into
pGEM11Z. A 1.7-kb fragment containing the CRE coding region, an intron
derived from the SV40 t-antigen gene, and a nuclear localisation signal was
extracted from the ACN cassette (23) by polymerase chain reaction (PCR)
with an XhoI site added to the 5¢ end and a HindIII site added to the 3¢
end. The CRE gene was then inserted into the XhoI and HindIII sites of
)3446⁄+28mGnRH-11Z. NotI and SalI were used to linearise the transgene
and to remove vector backbone.
The CRETeR vector was obtained from the laboratory of Dr Fred Wondisford
(24). Brieﬂy, the CRE fragment described above was ampliﬁed with HindIII
ends by PCR and cloned into the HindIII restriction enzyme site within the
multiple cloning site (MCS) of the pcDNA4⁄TO vector (Invitrogen, Carlsbad,
CA, USA). The pcDNA4⁄TO vector contains a CMV promoter, with two Tet
operators in the proximal promoter, 5¢ of the MCS. On the 3¢ side of the MCS
is a bovine growth hormone polyadenylation sequence. A CMV-TetR cassette
from pcDNA6⁄TO (Invitrogen) was then cloned downstream of CRE generating
the CRETeR vector. The CRETeR vector was digested with BglII to release
the CMV promoter, but retain part of the 2X Tet operator in the proximal
promoter. The 3446 bp mouse GnRH promoter was ampliﬁed from the
)3446⁄+28)11Z vector by PCR so that a SgrAI and a BamHI were added to
the 5¢ end. The 3¢ end was designed to restore the 2X Tet operator by inserting
into the BglII site with a BamHI end. This fragment was released from a
shuttle vector by excision with BamHI and inserted into the CRETeR vector to
produce GnRH-CRETeR. The vector was sequenced for veriﬁcation and was
linearised with SgrAI to remove vector backbone.
Animal production
The linearised vectors were puriﬁed and injected into fertilised oocytes
derived from a DC1 mouse to generate transgenic lines. Transgenic mice
were identiﬁed by PCR and Southern blot analysis. Hybridisation probes were
obtained by PCR using the primers (sense, 5¢-ATGCCCAAGAAGAA-
GAGGAAGGTG-3¢; antisense, 5¢-TCGCGAGCTCGACCGAACAAA-3¢) and the
ACN cassette as a template producing a 1.3-kb fragment. Southern blot
analysis was performed as previously described (25). PCR for genotyping
was performed using the primers (sense, 5¢-CGACCAAGTGACAGCAATGCT-3¢;
antisense, 5¢-GGTGCTAACCAGCGTTTTCGT-3¢). A 300-bp product will be pro-
duced in the presence of the transgene. Seven founder lines were produced
for the GnRH-CRE transgene and four were produced for the GnRH-CRETeR
transgene. Single founder lines were chosen based on immunohistochemistry
and the remaining lines were sacriﬁced.
Animal care and treatments
To induce CRE expression in the GnRH-CRETeR mice, doxycycline (DOX) was
administered as a 5-mg pellet that was inserted dorsally with a 10-gauge
trochar. The 21-day release doxycycline pellets were obtained from Innova-
tive Research of America (Sarasota, FL, USA). For the examination of CRE
expression, animals were sacriﬁced within 21 days to obtain tissue samples
for histology. For the examination of CRE recombinase activity using the
reporter mice, animals were sacriﬁced a minimum of 10 days after DOX cap-
sule implantation. All experiments were approved by the Institutional Animal
Care and Use Committees at Johns Hopkins Medical Institution, The Univer-
sity of Chicago or at The University of Maryland School of Medicine.
R26R⁄GnRH-CRE or GnRH-CRETeR bitransgenic mice
To assess the anatomical distribution of functional CRE recombinase
expression in the GnRH-CRE or GnRH-CRETeR mice they were crossed with
the Gt(ROSA)26Sor
tm1Sor reporter mouse (R26R) developed by Soriano (26)
and obtained from Jackson Laboratories (Bar Harbor, ME, USA). R26R mice
were genotyped using three primers, p1, 5¢-AAAGTCGCTCTGAGTTGTTAT-3¢,
p2, 5¢-GCGAAGAGTTTGTCCTCAACC-3¢, p3, 5¢GGAGCGGGAGAAATGGATATG-3¢.
For the wild-type allele, primers p3 (sense) and p1 (antisense) will produce
an approximately 550-bp amplicon. For the R26R allele, primers p2 (sense)
and p1 (antisense) produce an approximately 300-bp amplicon. GnRH-CRE-
TeR mice were also crossed with a related reporter mouse, the Gt(ROSA)26-
Sor
tm1(EYFP)Cos mouse (27) (a generous gift of Frank Costantino, Columbia
University) to conﬁrm the results in two separate reporter lines. Mice were
sacriﬁced at between 3 and 5 months of age for histological analysis.
Western blot analysis
GnRH-CRE mice were euthanised and hypothalamus, cerebral cortex, cerebel-
lum, liver, heart and lung were dissected and place into RIPA buffer (50 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 1 mM ethylenediaminetetraacetic
acid, 1 mM phenyl-methylsulfonyl ﬂuoride, 1 mM Na3VO4,1m M NaF, 40 ll⁄ml
Protease Inhibitor Cocktail (Roche Molecular Biochemicals, Indianapolis, IN,
USA) for western blot analysis. Tissues were homogenised with a Polytron
tissue homogeniser (Brinkmann Instruments Inc., Westbury, NY, USA).
For hypothalamic dissections, a single fragment was taken consisting of
tissue from 1 mm caudal to the mammillary bodies, rostrally to the olfac-
tory bulbs, 1 mm laterally beyond the lateral aspect of the median emi-
nence, and 3 mm dorsally.
Extracts were size fractionated by SDS-PAGE on an 8% resolving gel and
transferred to Protran (Perkin Elmer, Waltham, MA, USA) nitrocellulose mem-
brane by semi-dry transfer. Blots were stained with Ponceau solution [0.1%
(w⁄v) Ponceau S in 5% acetic acid] to visualise protein transfer. Polyclonal
antibody speciﬁc for CRE (Covance Research Products, Denver, PA, USA) was
used. Blots were then incubated with HRP conjugated secondary antibodies
(secondary antibodies obtained from Jackson Immunoresearch, West Grove,
PA, USA). Antibody binding was visualised using the ECL Plus reagent (Amer-
sham Pharmacia, Piscataway, NJ, USA).
Histology
All animals were anaesthetised with 100 mg⁄kg pentobarbital ip, adminis-
tered 10 IU heparin and perfused transcardially with saline containing 2%
sodium nitrite followed by 2.5% acrolein in buffered 4% paraformaldehyde
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tioned on a freezing microtome into 25 lm sections that are saved in 12
wells so that each well contains every twelth section. Sections were stored
in cryoprotectant antifreeze (29) until staining was initiated.
Sections were removed from the cryoprotectant antifreeze, rinsed in
potassium phophate-buffered saline (KPBS, 0.05 M phosphates, 0.9% NaCl,
pH 7.4), treated with a 1% NaBH4 solution (Sigma, St Louis, MO, USA),
rinsed, and then sections were incubated with anti-b-galactosidase antibody
(rabbit polyclonal, Chemicon Temecula, CA, USA; dilution 1 : 500 000), anti
CRE recombinase (Rabbit Polyclonal, Covance, Berkley, CA; USA; dilution
1 : 2 000 000), or anti-GnRH (rabbit polyclonal LR-1 gift of Dr Roger Guille-
min and Dr Robert Benoit; dilution 1 : 150 000) in KPBS with 0.4% Tri-
ton X-100, for 48 h at 4  C. After rinsing, the tissue was incubated for 1 h
at room temperature in biotinylated horse anti-rabbit IgG (heavy and light
chains; Vector Laboratories, Burlingame, CA, USA) at a concentration of
1 : 600 in KPBS with 0.4% Triton X-100, rinsed, and incubated for 1 h in
avidin-biotin complex solution (‘elite’ ABC kit, Vector Laboratories; 4.5 ll
each per ml incubation mixture). Visualisation was performed using DAB
either alone or with nickel salts (28).
Double-labelling was performed as previously reported (30–32). Brieﬂy,
the CRE staining was performed ﬁrst. After rinsing in KPBS then in 0.175 M
sodium acetate (NaOAc), the antibody-peroxidase complex was visualised
with a solution of NiSO4 (25 mg⁄ml), 3,3-diaminobenzidine HCl (NiDAB,
0.2 mg⁄ml), and H2O2 (0.83 ll of a 3% solution per ml of ﬁnal mixture) in
aqueous 0.175 M NaOAc that yielded a blue-black reaction product that was
conﬁned to the nucleus. In some cases, sections were treated with a b-Gal
Staining Set (Roche) to assess enzymatic activity. Sections were then stained
for GnRH as described for the single label above. The tissue was rinsed and
reacted using Tris saline (0.1 M solution pH 7.2) and DAB without nickel salts
as the chromogen (28). This procedure provided a brown reaction product.
After approximately 15–20 min, the tissue was rinsed in the acetate solution
or Tris-saline solution, rinsed in KPBS, and then placed into saline. The sec-
tions were mounted onto subbed slides, air-dried overnight, dehydrated in
alcohols, cleared in xylenes and mounted with Histomount and coverslipped.
Cell counts were performed on sections ranging from the caudal olfactory
bulb to the caudal hypothalamic aspect.
Results
GnRH-CRE and GnRH-CRETeR mice are fertile
Seven founders were produced that contained the GnRH-CRE trans-
gene (Fig. 1A) and four founders were produced that contained the
GnRH-CRETeR transgene (Fig. 4A). Two of the GnRH-CRE founder
mice did not transmit the transgene to their offspring and were
sacriﬁced. All of the remaining GnRH-CRE and GnRH-CRETeR foun-
der mice transmitted their transgene to their offspring. Mice from
each of these lines were bred for several generations and exhibited
normal fertility compared to other mice in our colony, indicating
that the expression of CRE in GnRH neurones did not impair repro-
ductive function for the GnRH-CRE mouse line. For this reason, it is
expected that CRE will not impact fertility in the Dox treated
GnRH-CRETeR mice, although this has yet to be tested.
CRE protein is localised to the hypothalamus
in GnRH-CRE mice
To determine the speciﬁcity of CRE expression, a western blot anal-
ysis was performed using homogenised tissues in GnRH-CRE mice
from the hypothalamus, cortex, cerebellum, liver, heart and lung.
Fig. 1(B) shows that CRE protein was only observed in the hypotha-
lamic tissue sample where GnRH neurones are localised.
CRE protein is localised to GnRH neurones
in GnRH-CRE mice
To speciﬁcally localise CRE protein to GnRH neurones, double label-
ling immunohistochemistry was performed on coronal sections of
mouse brains obtained from GnRH-CRE mice. A representative sec-
tion from a 4-month-old male mouse (no. 6102) is shown in Fig. 2.
On the left of Fig. 2, immunostaining is shown using only the poly-
clonal CRE antibody. Nuclear CRE staining (blue) is observed in cells
located in the olfactory tissues, ventral diagonal band of Broca,
medial preoptic area, and at the level of the organum vasculosum of
the lamina terminalis, all regions where GnRH neurones are located
(1, 4). On the right of Fig. 2, double-labelling with the polyclonal
CRE antibody and the LR1 polyclonal GnRH antibody is shown. CRE
again was observed as blue nuclear staining. GnRH appears as
brown cytoplasmic staining. An inset shows three of the double-
labelled neurones at · 250 magniﬁcation. Cell counts were per-
formed and 85% of stained neurones expressed both CRE and GnRH
(424 out of 498). 11.6% (n = 58) of GnRH stained neurones did not
clearly express Cre, and 3.2% (n = 16) of CRE stained neurones did
not express GnRH (Fig. 2). Brains from three other GnRH-CRE mice
from this same founder line (two female, no. 9721 and no. 8355
and one male, no. 357) were analysed as well and counts performed
on every six sections (as are all subsequent analyses) indicated that
similar percentages of GnRH neurones were colocalised with CRE
(no. 9721, 64 of 82; no. 8355, 60 of 69; and no. 8357, 71 of 88) and
that, similarly, few CRE expressing neurones were identiﬁed that
were not GnRH neurones (no. 9721, four neurones; no. 8355, two
neurones; no. 8357 and no. 8357, two neurones). Brains obtained
from other founders were found to have equal or lesser degrees of
colocalisation. These founders were ultimately sacriﬁced.
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Fig. 1. Targeting of CRE recombinase to the hypothalamus of transgenic
mice. (A) The construct used to target CRE recombinase is illustrated.
A )3446 bp fragment of the mouse gonadotrophin-releasing hormone
(GnRH) promoter was fused upstream of CRE recombinase. CRE recombinase
gene contains a Kozak initiation site, a nuclear localisation signal, an intron,
derived from the SV40 t-antigen gene and a poly(A) signal. (B) Western blot
analysis using an antibody speciﬁc for CRE protein in the indicated tissues
from a GnRH-CRE mouse, founder line 35. Tissues shown are hypothalamus
(hyp), cerebral cortex (ctx), cerebellum (cbl), liver (lvr), heart (hrt) and lung
(lng).
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neurones
To determine the extent to which CRE expression resulted in CRE
recombinase activity, GnRH-CRE mice were crossed with the
ROSA26 reporter mouse in which a loxP ﬂanked stop cassette pre-
vents constitutive expression of the b-galactosidase gene. Excision
of the stop cassette results in b-galactosidase gene expression in a
cell-speciﬁc manner (26). Histological staining for LacZ in a cell
indicates that CRE recombinase activity has occurred. Histological
analysis of six bitransgenic mice (no. 748 male, no. 752 male, no.
753 male, no. 751 female, no. 754 female and no. 755 female) aged
3–5 months indicated that 87% (416 of 476 neurones; 79.3  5.65
GnRH neurones per mouse and 69.3  5.14 neurones double-
labelled per mouse) of GnRH neurones expressed LacZ, and thus
CRE activity at some period during development (Fig. 3). This per-
centage was similar to the percentage of GnRH neurones express-
ing CRE in the adults examined (85%) (Fig. 2), suggesting that CRE
expressing GnRH neurones had exhibited Cre-recombinase activity.
There was also a population of LacZ expressing cells observed in
the lateral septum that did not express GnRH (Fig. 3). These cells
have also been observed by other investigators in GnRH-neurone
speciﬁc CRE mice (19, 21) as well as those using other reporter
systems (6, 33).
CRE recombinase activity is localised to GnRH neurones
in doxycycline treated GnRH-CRETeR mice
GnRH-CRETeR mice were crossed with the ROSA26 or ROSA26YFP
reporter mice. Bitransgenic mice aged 2–4 months were treated
with a doxyxyline capsule or left untreated. Mice were sacriﬁced a
minimum of 10 days following the insertion of the capsule.
Because recombinase activity, once complete, is not reversible, some
mice were analysed more than 21 days after the insertion of the
Total
neurones
GnRH+Cre GnRH  Cre 
498  424 58 16 
CRE-DAB/Ni (blue)  GnRH-DAB (brown) 
CRE-DAB/Ni (blue) 
Fig. 2. CRE recombinase is expressed in gonadotrophin-releasing hormone (GnRH) neurones. Coronal section of a brain from a single 4-month-old male
GnRH-CRE mouse (founder 35). Both sections are hypothalamic immediately caudal to the level of the organum vasculosum of the lamina terminalis. On the
left is staining for Cre alone with DAB⁄Ni showing nuclear blue staining. On the right is an adjacent section stained for Cre (blue nuclear) and for GnRH
(brown cytoplasmic). Both of these images are at · 100 magniﬁcation. Several neurones are boxed and shown in the inset at · 250 magniﬁcation. Scale
bars = 100 lm. Cell counts from all brain sections from this mouse are also shown.
Fig. 3. Gonadotrophin-releasing hormone (GnRH) neurones exhibit CRE
recombinase activity. Coronal sections (· 100 magniﬁcation) from a bitrans-
genic GnRH-CRE⁄ROSALacZ mouse. Section includes the medial and lateral
septum and the diagonal band of Broca (DBB). Tissue was treated with X-gal
to visualise b-galactosidase activity, seen as blue. GnRH neurones were stained
as above and are brown. A population of X-gal stained neurones are seen in
the lateral septum and do not express GnRH. A group of GnRH expressing
neurones are seen in the medial septum and DBB, all of which colocalise
with X-gal staining. The boxed region is further shown at · 250 magniﬁcation.
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expression of the LacZ [two mice (no. 1943 male and no. 1945 male
with DOX, no. 1994 male and no. 1946 female without DOX; repre-
sentative sections shown in Fig. 5)] or YFP gene (no. 1275 male and
no. 1264 female with DOX, no. 1278 male and no. 1265 female
without DOX; data not shown), was performed. Enzymatic analysis
of b-gal activity was also analysed (four mice, no. 8157 female, no.
3472 female, no. 3478 male, no. 3468 male, representative section
shown in Fig. 4B,C). Colocalisation of GnRH and CRE recombinase
activity was assessed from b-galactosidase or YFP protein was
observed in 88% of GnRH neurones (628 of 712 neurones, 89
GnRH neurones average per mouse with a SEM of 6.85 and an
average of 78.5 neurones average per mouse with a SEM of 7.24
exhibiting Cre recombinase activity). There were no regional differ-
ences noted between CRE expression in the GnRH-CRE mouse
(Fig. 2) or GnRH-CRETeR mice, and the GnRH-CRETeR CRE recom-
binase activity (Figs 4B,C and 5), except for the lateral septal popula-
tion of cells (Fig. 4B). This lateral septal population of neurones was
identical to those described above in the GnRH-CRE⁄ROSA26
mouse lines (Fig. 3). In mice bearing the GnRH-CRETeR transgene
and the ROSA26 reporter locus, and not treated with DOX, no CRE
recombinase activity was observed (Fig. 5, top right). In addition,
there was no signiﬁcant difference in the number of GnRH neuro-
nes in the DOX treated GnRH-CRETeR mice (89  6.85 neurones
per mouse) compared to the untreated GnRH-CRETeR mice
(94.75  6.3 neurones per mouse).
Discussion
The CRE⁄loxP system provides a valuable method to produce cell-
and tissue-speciﬁc gene deletions in mice. CRE, a bacteriophage
recombinase, can mediate a synaptic union of two loxP elements
located on the same linear DNA complex (11, 12). Thus, it has been
used to delete the region between properly oriented LoxP sites in a
speciﬁc gene (13, 15, 16, 22). In vivo recombination between loxP
sites occurs with high efﬁciency if CRE is expressed at a sufﬁciently
high level. For this reason, a number of transgenic mice have been
produced in which CRE expression has been placed under the con-
trol of a cell- or tissue-speciﬁc promoter and used to target gene
knockouts to speciﬁc cell types (15–17, 34). Systems have also been
developed that allow temporal regulation of CRE expression, either
by treatment with tetracycline or tamoxifen (22, 35, 36). The pres-
ent study describes the development of two transgenic mouse lines:
the GnRH-CRE line that expresses the CRE recombinase under
the control of the GnRH promoter; and the GnRH-CRETeR line
which expresses CRE in GnRH neurones following induction by
tetracycline.
The GnRH-CRE line was developed by producing mice containing
a transgene consisting of the CRE bacteriophage recombinase gene
regulated by a 3446-bp fragment of the mouse GnRH promoter
(Fig. 1A). This promoter region has previously been reported to be
sufﬁcient to target expression to GnRH neurones in the brain (5).
The GnRH-CRE mice express CRE in GnRH neurones in the hypo-
thalamus as assessed by double-label histological analysis (Fig. 2)
while exhibiting virtually undetectable levels of CRE in other cells
within the basal hypothalamus or in other tissues examined by
western blot analysis (Fig. 1B). In addition, when GnRH-CRE mice
are mated with the ROSA-LacZ reporter mice, offspring containing
both the CRE transgene and the reporter locus possessed b-galac-
tosidase expression in almost 87% of GnRH neurones, indicating
sufﬁcient GnRH neuronal CRE activity to induce recombination
within the ROSA locus (Fig. 3). b-galactosidase expression was
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Fig. 4. Gonadotrophin-releasing hormone (GnRH) neurones exhibit CRE recombinase activity in doxycycline treated GnRH-CRETeR mice. (A) The construct used
to produce the GnRH-CRETeR mouse is shown. A )3446 bp fragment of the mouse GnRH promoter was fused upstream of CRE recombinase as for the
GnRH-CRE mouse. The proximal region of the GnRH promoter was modiﬁed to insert two Tet operators (TetO2). In series, the transgene also contains the CMV
promoter regulating the Tet repressor gene. The rabbit b-globulin intron II is inserted between the promoter and the gene to enhance expression of the TetR
gene. (B) Coronal sections from a bitransgenic GnRH-CRETeR⁄ROSALacZ mouse treated with Dox. Section includes the medial and lateral septum and the DBB.
Tissue was treated with X-gal to visualise b-galactosidase activity and is seen as blue. GnRH neurones were stained as above and are brown. A population of
X-gal stained neurones are seen in the lateral septum and do not express GnRH. Nine GnRH expressing neurones are seen in the medial septum and DBB,
eight of which colocalised with X-gal staining. (C) GnRH neurones at the level of the organum vasculosum of the lamina terminalis⁄preoptic area at · 100
magniﬁcation. Ten GnRH immunostained neurones are depicted and nine co-stain blue indicating CRE recombinase activity. The boxed region is further dis-
played at · 250 magniﬁcation.
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that do not appear to express GnRH (Fig. 3). These neurones were
also labelled in doxycycline treated mice containing the GnRH-
CRETeR transgene and the ROSA-LacZ reporter gene (Fig. 4B). This
suggests that the GnRH promoter activity in these neurones is
ongoing and not due solely to an early developmental expression
of GnRH in this population of cells as has been previously reported
(33). These neurones may express a GnRH splice variant that is seen
in vitro (37) or express GnRH that is not translated, or have a very
low level of GnRH protein expression that cannot be detected using
available GnRH antibodies. Support for ongoing expression in other
populations of neurones comes from mapping studies in human
brains in which population of GnRH expressing neurones were
identiﬁed in the septum and dorsal preoptic area (38). Other groups
have reported this population of neurones in the lateral septum
expressing GnRH promoter reporter transgenes (6, 8, 18, 20, 21,
33). The signiﬁcance of this population to reproductive development
and function has yet to be determined. Since nearly all GnRH neu-
rones are expressing CRE, the GnRH-CRE mouse is suitable for the
constitutive disruption of genes in GnRH neurones when crossed
with mice containing ﬂoxed alleles of expressed genes.
Other studies have produced mouse lines expressing CRE in
GnRH neurones (18–21). The GnRH-iCRE mice produced by
Shimshek et al. (18, 19) were produced using the same 3446 bp
fragment of the murine promoter used to produce the GnRH-CRE
mouse, but fused to an improved CRE gene (iCRE). These mice
target CRE to GnRH neurones, but examination of CRE activity in
reporter mouse studies using the ROSA26 reporter mice showed
widespread CRE activity in the lateral septum, and in various other
non-GnRH expressing cells located in the lateral hypothalamus,
zona incerta, anterior hypothalamus, bed nucleus of the stria
terminalis, caudate putamen, paraventricular thalamic nuclei, central
amygdaloid nuclei, nucleus accumbens, posterior thalamic nuclei,
paraventricular nuclei and the reticular thalamus. The GnRH-
CRE⁄ROSA26 (Fig. 3) and GnRH-CRETeR⁄ROSA26 mice (Figs 4 and
5) reported in the present study exhibited far more restricted CRE
activity. Although unproven, this may be a function of the modiﬁ-
cations made to the CRE gene by Shimshek et al. (18, 19) that
produced a more robust CRE species that can exert recombinase
activity even in cells which have otherwise undetectable GnRH
promoter activity.
The LHRH::CRE transgenic mouse produced by Yoon et al. (21)
was constructed by inserting a CRE recombinase-poly(A) cassette
into the ﬁrst exon of the GnRH gene in a 212-kb BAC genomic
fragment. Almost 100% of CRE expressing neurones in these
mice expressed GnRH although whether nonbrain tissues were
examined was not documented in this manuscript. In crosses
with the ROSA26YFP reporter mouse (27), these mice also exhib-
ited CRE activity in the lateral septum and bed nucleus of the
stria terminalis, as seen in the GnRH-iCRE mice. Whether there
was more widespread CRE recombinase activity in more caudal
regions of the brain, as was reported in the GnRH-iCRE mouse,
was not addressed. Importantly, the additional ﬂanking regions
of the gene present in the BAC transgene used by Yoon et al.
(21) did not further restrict CRE activity compared to the GnRH-
CRE transgene used in the present study, suggesting that the
elements required to restrict expression are located in the
proximal 3446 bps of the promoter.
+Dox b-Gal –Dox b-Gal
–Dox GnRH +Dox GnRH
Fig. 5. CRE recombinase activity is induced by doxycycline in the gonadotrophin-releasing hormone (GnRH)-CRETeR mouse. Coronal sections from a
bitransgenic GnRH-CRETeR⁄ROSALacZ mouse treated with Dox (left, +DOX) and untreated (right, -DOX). The upper sections are stained for b-galactosidase
(blue⁄black) and the lower sections have been stained for GnRH (brown). Scale bars = 100 lm.
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ten (20). These mice are reported to express CRE in 97% of GnRH
neurones and to exhibit GnRH neurone-speciﬁc CRE recombinase
activity in 97% of GnRH neurones as assessed in crosses with the
ROSA26 reporter mouse. Few additional details were provided about
these mice, and it is not clear as to what extent CRE was expressed
in other neurones in the brain or in other tissues in the body. In
addition, no mention was made of whether there was the CRE
recombinase activity observed in non-GnRH neurones as reported
by Yoon et al. (21), Shimshek et al. (18, 19) and ourselves.
The GnRH-CRETeR transgene was produced by subcloning the
3446-bp mouse GnRH promoter into the CRETeR vector (24). The
proximal region of the promoter is modiﬁed to insert two Tet oper-
ators, binding sites for the Tet repressor (TetR). In addition, the
transgene contains the TetR gene under the regulation of the CMV
promoter, ensuring that the TetR protein will always be present to
constitutively repress CRE expression. In the presence of tetracy-
cline, or the more stable analogue doxycycline, the repressor is
removed from the Tet operators, allowing for GnRH promoter dri-
ven expression of the transgene. We produced mice containing this
transgene (Fig. 4A), the GnRH-CRETeR mouse, and have identiﬁed a
line that expresses functional CRE protein, as assessed in the
ROSA26 reporter mouse, in 88% of GnRH neurones in mice treated
with doxycycline (Figs 4B,C). In mice not treated with doxycycline,
CRE recombinase activity was not observed in GnRH neurones
(Fig. 5). When induced, the degree of CRE activity is strikingly simi-
lar to the expression of CRE in the GnRH-CRE mice, indicating that
neither the modiﬁcations to the proximal region of the GnRH pro-
moter or differences in transgene insertion site have interfered
appreciably with its function.
In summary, we report two mouse lines that express the CRE re-
combinase exclusively in GnRH neurones. The GnRH-CRE line
expresses CRE solely under the control of the murine GnRH pro-
moter. The second, GnRH-CRETeR, line is an inducible line that
expresses CRE in GnRH neurones only following treatment of the
mice with doxycycline. By crossing GnRH-CRE or GnRH-CRETeR
mice with mice containing a ﬂoxed gene, the effects of the loss of
the gene in GnRH neurones on the reproductive physiology of the
animal can be studied. The GnRH-CRETeR mice would have the
added beneﬁt of temporally controlling the GnRH neurone-speciﬁc
expression of CRE. Therefore, analysis of the role of a speciﬁc gene
in GnRH neurones can be explored in adult mice without possible
confounding developmental effects due to the absence of the gene.
Furthermore, mice would be able to serve as their own controls by
examining physiology before and after CRE recombinase induction.
The availability of these mice will allow investigators to explore, in
vivo, the importance of a vast array of genes on the central regula-
tion of reproductive function.
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